Two trades closed yesterday. Both losses. That's the headline, but it's not the story.

HON (Honeywell International) exited at a -6.7% loss after 19 days. SCHW (Charles Schwab Corp.) closed at -4.2% after 29 days. Zero wins, two losses, average return -5.4% across 24 days of average hold time. The numbers are what they are — and in a systematic portfolio running across a 422-ticker universe with 306 qualified names, days like this are the cost of admission. The risk overlay did its job: losses stayed small, defined, and isolated. Meanwhile, 148 open positions continue to carry the portfolio's upside. That's the math. The rest is noise.

The Trades That Closed

HON stock analysis September 2026 shows a conglomerate navigating a messy macro backdrop — aerospace recovery uneven, automation spending choppy, and the spin-off overhang still resolving. The position never found its footing. Nineteen days in, the signal reversed and the exit triggered. Small loss, clean exit. That's the HON trading signal working as designed: get out when the thesis breaks, preserve capital for the next setup.

SCHW stock analysis September 2026 tells a different story — rate sensitivity, deposit migration fears, and a yield curve that refuses to cooperate for broker-dealers. Twenty-nine days of chop, then the exit. The SCHW trading signal didn't chase a bounce that never came. Neither trade turned into a portfolio wound. That's the point.

Portfolio Pulse

One hundred forty-eight open positions. That's a lot of lines on the blotter, but the concentration isn't where you'd expect. The qualified pool — 306 names deep — means we're not forcing trades into illiquid corners. The signals that survive the anti-curve-fit filter are the ones with statistical edge on unseen data, not just pretty backtests. Most days, the portfolio hums along. Yesterday, two positions hit their stops. Today, the ledger resets.

What the Headlines Actually Said

Geopolitics dominated the newswires. Reuters reported China pressing Iran to rein in Houthi attacks after a Saudi appeal — a reminder that Red Sea shipping risk hasn't vanished, just migrated to the diplomatic track. Separately, U.S. allies are reportedly nervous about how a potential Trump-Xi dynamic would play over Taiwan. An Iranian delegation gets UN General Assembly visas. Lockheed Martin receives its first batch of Patriot interceptor parts from General Motors — a tangible data point in the defense supply chain reshoring story.

On the corporate side: Intel and Micron led portfolio gains in CNBC's coverage, while Johnson & Johnson's latest move "strengthens the case for owning it." Boeing's troubles got another column inch. Stephen Curry's Li-Ning shoe drops early next year (not tradeable, but fun). And an unnamed retailer is being accumulated after "a rare misstep" — CNBC's phrasing, not ours.

No Fed speeches. No CPI. No jobs data. Just a Thursday where the macro calendar went quiet and the micro stories took over.

What to Watch

INTC (Intel)

The foundry pivot remains the story. CNBC noted portfolio leadership today, but the real watch item is 18A yield progress and whether external customers (beyond the usual suspects) commit tape-outs. Foundry revenue ramp vs. OpEx bleed — that's the spreadsheet. Next catalyst: Intel Innovation in late September, then Q3 earnings in late October.

MU (Micron)

HBM3E qualification for NVIDIA's Blackwell platform is the binary driver. Micron guided to "meaningful revenue" in FY25 (starts September 2026). Watch for supply-chain commentary on DRAM pricing — spot prices have firmed, but contract negotiations for calendar 2027 are the real lever. Earnings late September.

JNJ (Johnson & Johnson)

The talc litigation overhang took another step toward resolution with the proposed $8B settlement trust (still subject to voting). MedTech margins are inflecting post-COVID normalization. Innovative Medicine grows mid-single-digits. Dividend aristocrat status intact. Next: Q3 earnings mid-October.

LMT (Lockheed Martin)

Patriot PAC-3 MSE production scaling — GM delivering interceptor components is a supply-chain de-risking milestone. F-35 TR-3/Block 4 delays persist but lot 18-20 negotiations are the near-term revenue gate. Classified backlog growth > reported backlog. Watch: Q3 earnings late October, plus any supplemental Ukraine funding movement.

GM (General Motors)

Beyond the LMT subcontract, the real story is Ultium Cells ramp (Lordstown, Spring Hill, Lansing) and whether EV profitability hits the guided timeline. Cruise restructuring continues quietly. Capital return framework (buybacks + dividend) remains aggressive. Q3 earnings late October.

BA (Boeing)

"What's ailing Boeing" is the headline, but the list is familiar: 737 MAX 7/10 certification delays, 777X push to 2026, defense fixed-charge losses, and a balance sheet that needs investment-grade defense. Kelly Ortberg's first 100 days — that's the clock. Watch: FAA audit progress, 737 delivery rate trajectory (targeting 38/mo), and any equity raise signaling.

HON (Honeywell International)

Post-exit, the name stays on the radar. The HON stock signal universe hasn't changed — aerospace aftermarket cycles, building automation exposure, and the pending Advanced Materials spin (targeting late 2026) are the three legs. If the spin executes cleanly, the sum-of-parts math gets interesting. Next catalyst: spin registration statement effectiveness.

SCHW (Charles Schwab Corp.)

Rate sensitivity cuts both ways. The SCHW stock signal will re-engage when the setup reappears — not before. Net new assets remain sticky ($100B+ annualized), but the earnings power is hostage to the short-end. Watch: September FOMC dot plot (already priced), then Q3 earnings mid-October for NIM trajectory.

The dashboard has every trade — winners, losers, and the ones still working. If you want to see the full ledger, it's there. No filter, no spin. Just the numbers.